Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT06057909 Recruiting - Healthy Clinical Trials

A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease

Start date: April 5, 2024
Phase:
Study type: Observational

The purpose of this research study is to investigate how the brain, memory, thinking, and motor behavior change both in individuals with movement and/or cognitive disorders, as well as healthy individuals. Researchers will look at measurements of memory, thinking, brain wave and muscle activity, daily functioning, and brain scans to learn more about brain disorders such as Alzheimer disease and Lewy body disease.

NCT ID: NCT06053125 Recruiting - Healthy Clinical Trials

A Study of Adipose Tissue in Adaptive Responses to Exercise

Start date: November 9, 2023
Phase: N/A
Study type: Interventional

The purpose of this research is to determine how exercise affects fat (adipose) tissue and how changes to adipose tissue that occur during and after exercise might improve health in aging and obesity.

NCT ID: NCT06052553 Recruiting - Healthy Clinical Trials

A Study of TopSpin360 Training Device

Start date: September 9, 2023
Phase: N/A
Study type: Interventional

This research is being done to investigate the novel neck strengthening device, TopSpin360 and its effectiveness on measures of neck strength and cognitive function

NCT ID: NCT06050356 Recruiting - Healthy Clinical Trials

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b

nTB-01
Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

Tuberculosis (TB) is an infection caused by bacteria passed from one person to another through the air when an infected person for instance coughs, speaks, or sneezes. This study tests the safety and vaccine-induced immune response of a new preventive TB vaccine called H107e/CAF®10b. H107e is a copy of protein parts from the bacterium causing tuberculosis, Mycobacterium tuberculosis, which are also called antigens. CAF®10b is an adjuvant which helps the body discover the antigen. The adjuvant and antigen are mixed together to formulate the final vaccine. The final formulated vaccine enhances the immune system's response against the antigen. This is a first-in-human study, meaning this vaccine is being given to people for the first time. The primary objective is to evaluate the safety of the vaccine and its components; however, the study will also evaluate the specific immune responses generated by the new vaccine. The study is divided into two parts, phase 1a and phase 1b. Phase 1a investigates unadjuvanted H107e, CAF®10b adjuvant, H107e/CAF®10b vaccine (low adjuvant dose), and H107e/CAF®10b vaccine (full adjuvant dose). The trial products are administered twice intramuscularly. H107e is also administered intranasally in one of the groups on Day 85. Phase 1b investigates H107e/CAF®10b, H107e/CAF®10b+Bacillus Calmette-Guérin (BCG), BCG, and placebo. A placebo is a look-alike substance that contains no active drug. All groups in phase 1b receive H107e intranasally on Day 211. A preventive TB vaccine such as H107e/CAF®10b should be able to introduce the body's immune system to antigens from Mycobacterium tuberculosis. This will result in memory in the immune system, meaning that when a person gets infected with Mycobacterium tuberculosis, the immune system will recognise and target the bacteria to prevent disease, thereby avoiding the need for antibiotic treatment and/or other treatments and their side effects.

NCT ID: NCT06049095 Recruiting - Healthy Clinical Trials

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Start date: October 17, 2023
Phase: Phase 1
Study type: Interventional

This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered LTG-001 in healthy male and female participants

NCT ID: NCT06048302 Recruiting - Healthy Clinical Trials

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

Start date: November 30, 2023
Phase: Phase 1
Study type: Interventional

To investigate the safety and pharmacokinetics in patients with moderate hepatic impairment compared to healthy participants after a single oral dose of obicetrapib (10 mg).

NCT ID: NCT06048016 Recruiting - Healthy Clinical Trials

Effect Of Scaling and Root Planning on ALP in Saliva and GCF In Periodontitis Patients Compared With Healthy Individuals

Start date: June 15, 2023
Phase: N/A
Study type: Interventional

The goal of this [interventional clinical trial] is to test effect of scaling and root plaining on Alkaline phosphatase in Saliva and Gingival crevicular fluid in periodontitis patients compared with healthy subjects The population from periodontitis patients compared with healthy individuals It aims to answer are: • 1_Alkaline phosphatase level in saliva and GCF. 2_Scaling and root plaining effect on Alkaline Phosphatase level. 0 participants will be asked to maintain their oral hygiene instructions. Researchers will compare [periodontitispatientsto healthyindividuals] to see if [AlkalinePhosphatase level].

NCT ID: NCT06042387 Recruiting - Healthy Clinical Trials

Diverse Ancestry Study in IBD

Start date: May 1, 2022
Phase:
Study type: Observational

Objective: To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD in diverse ancestries: African, African American, Black, Afro-Caribbean, Afro-Latino/a/x, Latino/a/x, Hispanic, or any other Black or Latin or indigenous ancestry.

NCT ID: NCT06041087 Recruiting - Healthy Clinical Trials

Bone and Inflammatory Outcomes - Nutrition and Exercise Trials

BIONEX
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

This study investigates whether dairy products will positively impact loading exercise-induced bone turnover and bone cell activity and/or the post-exercise inflammatory response in healthy young adults compared to a carbohydrate drink and/or water.

NCT ID: NCT06035276 Recruiting - Healthy Clinical Trials

Biosensor and Environmental Sensor Development Within the REMEDIA Project

Start date: August 28, 2023
Phase: N/A
Study type: Interventional

The aim of this proof-of-concept study is to obtain data that will contribute to the development of sensor devices (biosensor and environmental sensor) for patients with lung diseases (e.g. COPD). The study aims to validate our previous results from healthy subjects by joint testing of the biosensor and environmental device in a real-world setting. Healthy subjects and COPD subjects will be exposed to air of a traffic dense urban region ("urban" air) and to filtered indoor air ("clean" air) during activity and rest. Environmental and biomarker sensors will be used to measure several biomarkers and environmental conditions.